Skip to Content

Zheijiang Guobang Pharmaceuticals, China, 2025

GMP Audit Report

Company
Zheijiang Guobang Pharmaceuticals

Product(s)
diclazuril, enrofloxacine, marbofloxacine

Country
China

Audit Year
2025


0.00 € 0.00 €
0.00 €